Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
11:29am, Friday, 10'th Mar 2023
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
09:38am, Friday, 10'th Mar 2023 Zacks Investment Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
01:00pm, Thursday, 09'th Mar 2023 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sa
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
09:11am, Thursday, 09'th Mar 2023
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sa
3 No-Brainer Stocks to Buy With $400 Right Now
10:21am, Wednesday, 08'th Mar 2023 The Motley Fool
A reasonably small amount of money can go a long way when it's invested in innovative businesses.
3 No-Brainer Stocks to Buy With $400 Right Now
05:21am, Wednesday, 08'th Mar 2023
Last year, the Dow Jones, S&P 500, and Nasdaq Composite produced their worst returns since 2008. History shows that big stock market declines are the ideal time for long-term investors to go shopping.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
09:24am, Tuesday, 07'th Mar 2023 Zacks Investment Research
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
06:01am, Tuesday, 07'th Mar 2023
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
AstraZeneca says cancer drug Enhertu showed positive results
07:33am, Monday, 06'th Mar 2023 MarketWatch
Enhertu--trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo--had met prespecified criteria for objective response rate and duration of response.
AstraZeneca says cancer drug Enhertu showed positive results
02:33am, Monday, 06'th Mar 2023
AstraZeneca PLC on Monday said its cancer drug Enhertu has shown clinically meaningful and durable responses across multiple HER2-expressing advanced solid tumors in its DESTINY-PanTumor02 Phase II tr
AstraZeneca refinances $2.25bn of debt
03:11am, Wednesday, 01'st Mar 2023
AstraZeneca PLC (LSE:AZN), the UK's largest pharmaceuticals group, has announced a $2.25bn global bond offering. The debt issue, which consists of three tranches, is expected to close on March 3 an
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
09:51pm, Tuesday, 28'th Feb 2023 The Motley Fool
It's not a good day for investors when their company reports a shocking plunge into the red.
Why Compugen Shares Are Up Today
05:17pm, Tuesday, 28'th Feb 2023 The Motley Fool
The company released its fourth-quarter and full-year results after the bell Monday.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
05:05pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
How To Use A Cash-Secured Put Option Strategy
12:18pm, Tuesday, 28'th Feb 2023
A cash-secured put has a number benefits as an options strategy. It can pick up shares at a lower price or generate income.
